Latest & greatest articles for hypertension

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hypertension or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hypertension and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hypertension

1. The Japanese Hypertension Guidelines

The Japanese Hypertension Guidelines Page 36 · MED CHECK December 2019/ Vol.5 No.15 C N o 15 M ED HECK 2 0 1 9 Problems in Selection of Members for Guidelines Hypertension Guidelines Part 1, Part 2 Diovan Scandal High Risk of Death from Tamiflu and Xofluza Editorial The Japanese Hypertension Guidelines 2019 Problems in Selection of Members Review Critical Assessment of Hypertension Guidelines Part 1 Scientific evidence for the hypertension guidelines 2019 is poor Critical Assessment (...) of Hypertension Guidelines Part 2 NICE (UK) recommends treatment if blood pressure is 160/100 or over Neglect of Correcting Scientific Fraud: Ruling over Diovan Scandal Advrse Reactions Tamiflu: Death After Abnormal Behaviour in Teenagers Revisited High Risk of Death from Tamiflu and Xofluza CONTENTS (December 2019, Vol. 5, No. 15 ) 37 38 44 48 50 52 Volume 5 December C M ED HECKMED CHECK December 2019/ Vol.5 No.15 · Page 37 References The Japanese Hypertension Guidelines 2019: Problem in Selection of Members

2020 Med Check - The Informed Prescriber

2. Impact of Moderate Aerobic Training on Physical Capacities of Hypertensive Obese Elderly. (PubMed)

Impact of Moderate Aerobic Training on Physical Capacities of Hypertensive Obese Elderly. The association of old age and chronic conditions, such as hypertension and obesity, can lead to larger decreases in the physical capacities of elderly, compared with their healthy counterparts. Physical exercise has been demonstrated to be efficient in postponing this phenomenon, mainly strength training. However, little is known about the effect of aerobic training on this condition. The aim of this work (...) was to investigate the impact of 12 weeks of moderate-intensity aerobic training on the physical capacities of hypertensive obese older women. Aerobic power, lower limb muscle power, upper limb muscle strength, endurance, and flexibility of 19 hypertensive obese elders were evaluated. Afterward, patients were blindly randomized into control group (CG) and exercise group (EG). EG underwent three sessions/week of 60 min of moderate-intensity aerobic training, during 12 weeks. EG showed increases in VO2max compared

Full Text available with Trip Pro

2019 Gerontology & geriatric medicine Controlled trial quality: uncertain

3. Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis

Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis The DETECT algorithm has been developed to identify SSc patients at risk for pulmonary arterial hypertension (PAH) yielding high sensitivity but low specificity, and positive predictive value. We tested whether cardiopulmonary exercise testing (CPET) could improve the performance of the DETECT screening strategy.Consecutive SSc patients over a 30-month period (...) were screened with the DETECT algorithm and positive subjects were referred for CPET before the execution of right-heart catheterization. The predictive performance of CPET on top of DETECT was evaluated and internally validated via bootstrap replicates.Out of 314 patients, 96 satisfied the DETECT application criteria and 54 were positive. PAH was ascertained in 17 (31.5%) and pre-capillary pulmonary hypertension in 23 (42.6%) patients. Within CPET variables, the slope of the minute ventilation

2019 EvidenceUpdates

4. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report

Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report Therapy for Pulmonary Arterial Hypertension in Adults - CHEST Follow CHEST: Email/Username: Password: Remember me Search Terms Search within Search Share this page Volume 155, Issue 3, Pages 565–586 To read this article in full, please review your options for gaining access at the bottom of the page. Therapy for Pulmonary Arterial Hypertension in Adults Update of the CHEST Guideline (...) . In these situations, other factors, such as patient preferences & values, cost, and insurance coverage, may guide decision-making. CCB = calcium channel blocker; 6MWD = 6-min walk distance; FC = functional class; PAH = pulmonary arterial hypertension; PH = pulmonary hypertension; RV = right ventricular; WHO = World Health Organization. Figure 1 Guideline algorithm for pharmacologic therapy for PAH in adults. Where multiple drug options are provided, there is no comparative effectiveness data to suggest greater

2019 American College of Chest Physicians

5. Updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension

Updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT - The Journal of Heart and Lung Transplantation Email/Username: Password: Remember me Search Terms Search within Search Access provided by Volume 38, Issue 9, Pages 879–901 2019 updated consensus (...) statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT x Georg Hansmann Affiliations Department of Pediatric Cardiology and Critical Care, Hannover Medical School, Hannover, Germany Correspondence Reprint requests: Georg Hansmann, MD, PhD, Department of Pediatric Cardiology and Critical Care, Hannover Medical School, Carl-Neuberg-Str 1 Hannover 30625 Germany. Telephone: +49 511-532

2019 International Society for Heart and Lung Transplantation

6. Hydrochlorothiazide and Squamous Cell Skin Cancer: Remember when hypertension was easy?

Hydrochlorothiazide and Squamous Cell Skin Cancer: Remember when hypertension was easy? 1 Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care (...) research. www.acfp.ca November 25, 2019 (en français) Hydrochlorothiazide and Squamous Cell Skin Cancer: Remember when hypertension was easy? Clinical Question: Does hydrochlorothiazide increase the risk of squamous cell carcinoma (SCC) of the skin? Bottom Line: Observational data suggest an association between hydrochlorothiazide and the risk of SCC. Causation has not been proven. Risk appears to consistently increase with dose and duration (example: 5 years of use increases risk 3-4 times). Baseline

2019 Tools for Practice

7. In patients taking a beta blocker for uncomplicated hypertension, what is the best way to taper it off?

In patients taking a beta blocker for uncomplicated hypertension, what is the best way to taper it off? Chiefs’ Inquiry Corner 11/4/19 – Clinical Correlations Search Chiefs’ Inquiry Corner 11/4/19 November 4, 2019 2 min read Beta blockers (BBs) have fallen out of favor as first-line, or even second-line, treatment options for hypertension. And as patients’ medical regimens gradually drop BBs, concerns may arise about the rebound phenomenon we learn in medical school. With chronic beta blocker

2019 Clinical Correlations

8. Therapeutic-induced hypertension in patients with noncardioembolic acute stroke

Therapeutic-induced hypertension in patients with noncardioembolic acute stroke To evaluate the safety and efficacy of induced hypertension in patients with acute ischemic stroke.In this multicenter randomized clinical trial, patients with acute noncardioembolic ischemic stroke within 24 hours of onset who were ineligible for revascularization therapy and those with progressive stroke during hospitalization were randomly assigned (1:1) to the control and intervention groups. In the intervention (...) patients were included in the intervention and control groups, respectively. After adjustment for age and initial stroke severity, induced hypertension increased the occurrence of the primary (odds ratio 2.49, 95% confidence interval [CI] 1.25-4.96, p = 0.010) and secondary (odds ratio 2.97, 95% CI 1.32-6.68, p = 0.009) efficacy endpoints. Sixty-seven (88.2%) patients of the intervention group exhibited improvements in NIHSS scores of ≥2 points during induced hypertension (mean SBP 179·7 ± 19.1 mm Hg

2019 EvidenceUpdates

9. Causal association between periodontitis and hypertension: evidence from Mendelian randomization and a randomized controlled trial of non-surgical periodontal therapy

Causal association between periodontitis and hypertension: evidence from Mendelian randomization and a randomized controlled trial of non-surgical periodontal therapy Inflammation is an important driver of hypertension. Periodontitis is a chronic inflammatory disease, which could provide a mechanism for pro-hypertensive immune activation, but evidence of a causal relationship in humans is scarce. We aimed to investigate the nature of the association between periodontitis and hypertension.We (...) on the effects of treatment of periodontitis on BP. One hundred and one hypertensive patients with moderate/severe periodontitis were randomized to intensive periodontal treatment (IPT; sub- and supragingival scaling/chlorhexidine; n = 50) or control periodontal treatment (CPT; supragingival scaling; n = 51) with mean ambulatory 24-h (ABPM) systolic BP (SBP) as primary outcome. Intensive periodontal treatment improved periodontal status at 2 months, compared to CPT. This was accompanied by a substantial

2019 EvidenceUpdates

10. Endothelin receptor antagonists for pulmonary arterial hypertension

Endothelin receptor antagonists for pulmonary arterial hypertension '); } else { document.write(' '); } ACE | Endothelin receptor antagonists for treating pulmonary arterial hypertension Search > > Endothelin receptor antagonists for treating pulmonary arterial hypertension - Endothelin receptor antagonists for treating pulmonary arterial hypertension Published on 2 September 2019 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Ambrisentan 5 mg and 10 (...) mg tablets for treating adults with a confirmed diagnosis of WHO Functional Class II or III pulmonary arterial hypertension (PAH) who have one of the following PAH aetiologies: Idiopathic PAH; Heritable or familial PAH; PAH associated with connective tissue disease; Anorexigen-induced PAH; or PAH associated with HIV infection. Subsidy status Ambrisentan 5 mg and 10 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication. MAF assistance

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

11. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial

Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial The Hygia Chronotherapy Trial, conducted within the clinical primary care setting, was designed to test whether bedtime in comparison to usual upon awakening hypertension therapy exerts better cardiovascular disease (CVD) risk reduction.In this multicentre, controlled, prospective endpoint trial, 19 084 hypertensive patients (10 614 men/8470 women, 60.5 ± 13.7 years of age) were assigned (1:1 (...) ) to ingest the entire daily dose of ≥1 hypertension medications at bedtime (n = 9552) or all of them upon awakening (n = 9532). At inclusion and at every scheduled clinic visit (at least annually) throughout follow-up, ambulatory blood pressure (ABP) monitoring was performed for 48 h. During the 6.3-year median patient follow-up, 1752 participants experienced the primary CVD outcome (CVD death, myocardial infarction, coronary revascularization, heart failure, or stroke). Patients of the bedtime, compared

2019 EvidenceUpdates

12. A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial. (PubMed)

A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial. Hypertension is the leading cause of cardiovascular disease globally. Despite proven benefits, hypertension control is poor. We hypothesised that a comprehensive approach to lowering blood pressure and other risk factors, informed by detailed analysis of local barriers, would be superior to usual care in individuals with poorly controlled or newly diagnosed (...) hypertension. We tested whether a model of care involving non-physician health workers (NPHWs), primary care physicians, family, and the provision of effective medications, could substantially reduce cardiovascular disease risk.HOPE 4 was an open, community-based, cluster-randomised controlled trial involving 1371 individuals with new or poorly controlled hypertension from 30 communities (defined as townships) in Colombia and Malaysia. 16 communities were randomly assigned to control (usual care, n=727

2019 Lancet

13. Nonsteroidal Anti-Inflammatory Drugs and Hypertension: Safety

Nonsteroidal Anti-Inflammatory Drugs and Hypertension: Safety Nonsteroidal Anti-Inflammatory Drugs and Hypertension: Safety | CADTH.ca Find the information you need Nonsteroidal Anti-Inflammatory Drugs and Hypertension: Safety Nonsteroidal Anti-Inflammatory Drugs and Hypertension: Safety Last updated: January 24, 2019 Project Number: RB1300-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the evidence associated with the development (...) of hypertension upon the use of nonsteroidal anti-inflammatory drugs to treat acute pain? Key Message No relevant literature was identified regarding the evidence associated with the development of hypertension upon the use of nonsteroidal anti-inflammatory drugs to treat acute pain. Files Rapid Response Summary of Abstracts Published : January 24, 2019 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

14. Natriuretic Peptide Testing for Pulmonary Arterial Hypertension: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Natriuretic Peptide Testing for Pulmonary Arterial Hypertension: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Natriuretic Peptide Testing for Pulmonary Arterial Hypertension: Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Natriuretic Peptide Testing for Pulmonary Arterial Hypertension: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Natriuretic Peptide Testing for Pulmonary Arterial Hypertension: Clinical (...) Effectiveness, Cost-Effectiveness, and Guidelines Last updated: July 24, 2019 Project Number: RB1358-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical utility of natriuretic peptide testing for prognosis or guiding therapy for pulmonary arterial hypertension? What is the cost-effectiveness of natriuretic peptide testing for prognosis or guiding therapy for pulmonary arterial hypertension? What are the guidelines

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

15. Diagnosis of chronic thromboembolic pulmonary hypertension: A Canadian Thoracic Society clinical practice guideline update

Diagnosis of chronic thromboembolic pulmonary hypertension: A Canadian Thoracic Society clinical practice guideline update CTS GUIDELINES AND POSITION PAPERS Diagnosis of chronic thromboembolic pulmonary hypertension: A Canadian Thoracic Society clinical practice guideline update Doug Helmersen a , Steeve Provencher b , Andrew M. Hirsch c , Anne Van Dam d , Carole Dennie e , Marc De Perrot f , Lisa Mielniczuk g , Naushad Hirani a , George Chandy h , John Swiston i , Dale Lien j , Nick H. Kim k (...) , Marion Delcroix l , and Sanjay Mehta m a Pulmonary Hypertension Program, Division of Respiratory Medicine, Peter Lougheed Centre, University of Calgary, Calgary, Alberta, Canada; b Institut Universitaire de Cardiologie et de Pneumologie de Qu ebec, Universit e de Laval, Quebec, Quebec, Canada; c Centre for Pulmonary Vascular Disease, Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada; d Canadian Thoracic Society, Ottawa, Ontario, Canada; e Thoracic and Cardiac

2019 Canadian Thoracic Society

16. Transjugular Intrahepatic Portosystemic Stent-Shunt (TIPSS) in the management of portal hypertension

Transjugular Intrahepatic Portosystemic Stent-Shunt (TIPSS) in the management of portal hypertension British Society of Gastroenterology Transjugular Intrahepatic Portosystemic Stent-Shunt (TIPSS) in the management of portal hypertension. Contents Guidelines development group 3 Abstract 4 Executive summary of recommendations 4 Research recommendations: 12 Patient summary 14 Introduction 17 Guideline development 17 Assessing the quality of guidelines: The AGREE II instrument 17 History of TIPSS (...) 19 Indications for TIPSS 22 TIPSS for Variceal Bleeding 22 TIPSS for ascites, hepatic hydrothorax and hepatorenal syndrome 27 TIPSS for ascites 27 TIPSS for hepatic hydrothorax 30 TIPSS for hepatorenal syndrome (HRS) 31 TIPSS and Budd Chiari Syndrome 32 TIPSS prior to non-hepatic surgery in patients with portal hypertension (prophylactic TIPSS) 34 TIPSS and idiopathic non-cirrhotic portal hypertension (INCPH) 36 TIPSS in portal vein thrombosis 37 Patient selection 39 Hepatic encephalopathy 39 Pre

2019 British Society of Gastroenterology

17. Prostanoids and their analogues for the treatment of pulmonary hypertension in neonates. (PubMed)

Prostanoids and their analogues for the treatment of pulmonary hypertension in neonates. Persistent pulmonary hypertension of the newborn (PPHN) is a disease entity that describes a physiology in which there is persistence of increased pulmonary arterial pressure. PPHN is characterised by failure to adapt to a functional postnatal circulation with a fall in pulmonary vascular resistance. PPHN is responsible for impairment in oxygenation and significant neonatal mortality and morbidity

2019 Cochrane

18. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. (PubMed)

Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Hypertension is the most common medical disorder in pregnancy, complicating one in ten pregnancies. Treatment of severely increased blood pressure is widely recommended to reduce the risk for maternal complications. Regimens for the acute treatment of severe hypertension typically include intravenous medications. Although (...) effective, these drugs require venous access and careful fetal monitoring and might not be feasible in busy or low-resource environments. We therefore aimed to compare the efficacy and safety of three oral drugs, labetalol, nifedipine retard, and methyldopa for the management of severe hypertension in pregnancy.In this multicentre, parallel-group, open-label, randomised controlled trial, we compared these oral antihypertensives in two public hospitals in Nagpur, India. Pregnant women were eligible

Full Text available with Trip Pro

2019 Lancet Controlled trial quality: predicted high

19. Calcium supplementation commencing before or early in pregnancy, for preventing hypertensive disorders of pregnancy. (PubMed)

Calcium supplementation commencing before or early in pregnancy, for preventing hypertensive disorders of pregnancy. The hypertensive disorders of pregnancy include pre-eclampsia, gestational hypertension, chronic hypertension, and undefined hypertension. Pre-eclampsia is considerably more prevalent in low-income than in high-income countries. One possible explanation for this discrepancy is dietary differences, particularly calcium deficiency. Calcium supplementation in the second half (...) to be inadequate. This is an update of a review first published in 2017.To determine the effect of calcium supplementation, given before or early in pregnancy and for at least the first half of pregnancy, on pre-eclampsia and other hypertensive disorders, maternal morbidity and mortality, and fetal and neonatal outcomes.We searched the Cochrane Pregnancy and Childbirth Trials Register (31 July 2018), PubMed (13 July 2018), ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP; 31

2019 Cochrane

20. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. (PubMed)

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Spironolactone is effective at reducing blood pressure in patients with uncontrolled resistant hypertension. However, the use of spironolactone in patients with chronic kidney disease can be restricted by hyperkalaemia. We evaluated use of the potassium binder patiromer to allow more persistent use (...) of spironolactone in patients with chronic kidney disease and resistant hypertension.In this phase 2 multicentre, randomised, double-blind, placebo-controlled study, we enrolled participants aged 18 years and older with chronic kidney disease (estimated glomerular filtration rate 25 to ≤45 mL/min per 1·73 m2) and uncontrolled resistant hypertension from 62 outpatient centres in ten countries (Bulgaria, Croatia, Georgia, Hungary, Ukraine, France, Germany, South Africa, the UK, and the USA). Patients meeting all

2019 Lancet